<DOC>
	<DOCNO>NCT01116817</DOCNO>
	<brief_summary>The aim study describe compare percentage patient infect HIV-1 maintain complete virology suppression CSF ( CSF CV 1 copy / mL ) patient CV &lt; 50 copy / mL treat stable antiretroviral therapy least 3 year LPV / r 400/100 mg twice daily + 2 NRTI .</brief_summary>
	<brief_title>Study Compare Virologic Efficacy Cerebrospinal Fluid ( CSF ) Neurocognitive State Patients Infected HIV-1 Long-term Treatment ( &gt; 3 Years ) With Lopinavir / Ritonavir Monotherapy</brief_title>
	<detailed_description>Combinations antiretroviral management HIV infection recommend main treatment guideline include combination two nucleoside analogue reverse transcriptase ( NRTI ) non-nucleoside reverse transcriptase ( NNRTI ) inhibitor protease ( IP ) .1 However , NRTIs inhibit mitochondrial DNA gamma polymerase , cause mitochondrial dysfunction , turn result related adverse effect peripheral neuropathy , pancreatitis , hepatitis , abnormal lipid profile lipodystrophy . Therefore , advisable design search therapeutic strategy avoid prolonged exposure NRTIs adverse event . IP monotherapy strategy simplification , induction period standard triple therapy may useful minimize risk mitochondrial toxicity NRTIs . Additionally , strategy may useful improve treatment adherence , reduce cost preserve future treatment option . In sense , monotherapy lopinavir / ritonavir ( LPV / r ) effective option treatment HIV-1 simplification strategy routine clinical practice.3 OK04 study show patient sustained viral suppression simplify monotherapy LPV / r , rate viral load &lt; 50 copy / mL similar patient continue standard triple therapy.4 , 5 However , virological efficacy strategy CSF compartment question author . Like protease inhibitor , lopinavir poor penetration CSF . Thus , despite concentration lopinavir CSF usually exceed inhibitory concentration ( IC50 ) wild strain HIV , possible patient may present lopinavir concentration insufficient achieve sustain suppression viral replication compartment . In sense , accord result recent study , 10 % patient treat lopinavir / ritonavir monotherapy may present detectable level viral load CSF maintain CV &lt; 50 copy / mL plasma.9 On hand , half patient antiretroviral therapy ( HAART ) , despite achieve virologic control treatment perform properly , neurocognitive dysfunction.10 This associate multiple risk factor , include presence HIV CSF.11 In fact , even though achieve undetectable viral load plasma , 40 % patient HAART show presence virus CSF.12 This also associate worse neurocognitive functioning . Therefore , maximum control viral replication show priority improvement CNS dysfunction . Based , objective study explore evaluate virological efficacy safety long-term neurocognitive level ( &gt; 3 year ) monotherapy lopinavir / ritonavir strategy simplify antiretroviral therapy patient infected HIV .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Experimental group : 1 . Patients diagnosis HIV infection , stable treatment least 3 year LPV/r monotherapy , inclusion patient least 2 year permit possible include expect number patient . 2 . Initiating monotherapy lopinavir / ritonavir maintain value plasma HIV1 RNA undetectable ( cv &lt; 50 copy / mL ) . 3 . Maintain complete virologic suppression ( CV &lt; 50 copy / ml ) plasma least 3 year treatment LPV / r monotherapy . ( Or 2 year , comply expected number patient least 3 year LPV / r monotherapy ) . 4 . Good adherence treatment ( &gt; 90 % ) . 5 . Signing informed consent . Control group : 1 . Patients diagnosis HIV infection , stable treatment least 3 year LPV/r 400/100 mg twice day + 2 ITIAN , inclusion patient least 2 year permit possible include expect number patient . 2 . Maintain complete virologic suppression ( CV &lt; 50 copy / ml ) plasma least 3 year treatment LPV / r monotherapy . ( Or 2 year , comply expected number patient least 3 year LPV / r 400/100 mg 2 twice day + 2 ITIAN ) . 3 . Patients put pair experimental one follow characteristic : age , sex , presence previous virologic failure , nadir CD4 + T lymphocytes viral load &lt; 50 copy / mL time prior inclusion study . Patients diagnosis HIV . 4 . Good adherence treatment ( &gt; 90 % ) . 5 . Signing informed consent . 1 . Vaccine administration , acute chronic uncontrolled infection 2 month prior inclusion medical assessment opinion investigator , might compromise result study . 2 . Pregnancy breastfeed . 3 . Therapies include interferon , interleukin2 , cytotoxic chemotherapy immunosuppressant baseline . 4 . Do sign inform consent . 5 . Existence contraindication performance lumbar puncture . 6 . Presence psychiatric disorder psychopharmacological treatment . 7 . Active alcohol consumption ( &gt; 50 g / day ) illicit drug . 8 . Existence current past opportunistic infection involve CNS function alteration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Long-term Lopinavir/ritonavir monotherapy</keyword>
	<keyword>neurocognitive performance</keyword>
	<keyword>ultrasensitive CSF-viraemia</keyword>
</DOC>